Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease
RightsArchived with thanks to JAMA
MetadataShow full item record
Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry. Among patients of East Asian ancestry, NUDT15 variants are associated with thiopurine-induced myelosuppression (TIM).